ADHD Drug Shortage Problematic Between DEA and Manufacturers

ADHD Shortage – ADHD drugs are on short supply and the shortage is blamed on the bad relationship between the manufacturers of the meds and the Drug Enforcement Administration.

The disorder effects nine percent of kids between the ages of 5 and 17, with about 4 percent of the adult population being diagnosed with the attention problem. Drugs such as Ritalin or Adderall are prescribed to treat the conditions. However, they can be easily abused and the DEA has set a quota on how many pills can be manufactured.

Furthermore, the manufacturers use that to their advantage by producing more of the expensive name brand pills then a generic one since the DEA’s quota does not specify any ratio’s between how many pills of each kind they should produce. Leaving less of the more affordable pills in the market as an option.

For some who need to treat their children, their may be only one kind of ADHD medication that will work and if there is no generic available, they may not be able to afford the more expensive name brand pill, leaving them no choice but to not medicate the child.

The FDA has tried to remedy the situation by reaching out to the DEA without any success.

“We have reached out to the D.E.A. and told them that there are shortage issues,” said Valerie Jensen, associate director of the F.D.A.’s drug shortage program. “But the quota issues are outside of our area of responsibility.”

The DEA maintains however, there is no problem. “We believe there is plenty of supply,” said DEA special agent Gary Boggs.

Meanwhile, Reuters also reports that the most popular drug for ADHD is Adderall and a shortage of the medication is likely to remain.




Leave a Reply

Your email address will not be published. Required fields are marked *